The Role of Type I Interferon in Interstitial Lung Disease

• Conditions: Connective TIssue Diseases; rheumatic diseases; 10003816

• Registration Number: NL-OMON56690
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 120

Inclusion Criteria

In order to be eligible to participate in this study as a patient, a subject
must meet all of the
following criteria:
1.Established diagnosis of:
-SAD without ILD (according to the latest ACR-EULAR criteria)
-SAD with ILD (according to the latest ACR-EULAR criteria and ILD diagnostics)
-IPAF patients (according to latest consensus) [9]
-IPF patients (according to latest diagnostics) [11]
2.Age >= 18 years
3. Providing informed consent after reading patient information.

Exclusion Criteria

A potential subject who meets any of the following criteria will be excluded
from participation in this study:
1.No established diagnosis of SAD, IPAF or IPF.
2.Refusal to participate in the study.
3.Insufficient knowledge of the Dutch language.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Our main study parameters will be IFN-I activation at baseline and after<br /><br>standard care immunosuppressants and relation between IFN-I and fibrosis in an<br /><br>in vitro model. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable. </p><br>